These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30006436)

  • 1. Updating formulations for compounded oral liquid medications in a university health system.
    Stumpf JL; Leja N; Ciarkowski SL; Salah S; Schaeffler KL
    Am J Health Syst Pharm; 2018 Sep; 75(18):1394-1398. PubMed ID: 30006436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Devices for securing and administering pediatric compounded oral liquids: survey results from French university hospitals.
    Cavelier M; Hervouët C; Varin R; Gondé H
    Eur J Pediatr; 2024 Jun; 183(6):2805-2810. PubMed ID: 38573361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in compounding of oral liquids for pediatric patients: a patient safety concern.
    Rood JM; Engels MJ; Ciarkowski SL; Wagenknecht LD; Dickinson CJ; Stevenson JG
    J Am Pharm Assoc (2003); 2014; 54(4):383-9. PubMed ID: 25063260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability and consistency of compounded oral liquid levothyroxine formulations.
    Meyer LM; Stephens K; Carter CA; Pickard W; Johnson PR; Eagerton DH
    J Am Pharm Assoc (2003); 2020; 60(6):e168-e172. PubMed ID: 32591200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardization of compounded oral liquids for pediatric patients in Michigan.
    Engels MJ; Ciarkowski SL; Rood J; Wang B; Wagenknecht LD; Dickinson CJ; Stevenson JG
    Am J Health Syst Pharm; 2016 Jul; 73(13):981-90. PubMed ID: 27325879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practices of pharmacies that compound extemporaneous formulations.
    Treadway AK; Craddock D; Leff R
    Am J Health Syst Pharm; 2007 Jul; 64(13):1403-9. PubMed ID: 17592006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiological quality of pediatric oral liquid formulations.
    Cabañas Poy MJ; Cañete Ramírez C; González di Lauro SX; Rodríguez Garrido V; Roig Carbajosa G; Fernández-Polo A; Clemente Bautista S
    Farm Hosp; 2016 Sep; 40(5):427-35. PubMed ID: 27570992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH determination as a quality standard for the elaboration of oral liquid compounding formula.
    Vázquez-Blanco S; González-Freire L; Dávila-Pousa MC; Crespo-Diz C
    Farm Hosp; 2018 Nov; 42(6):221-227. PubMed ID: 30381041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Always the Right Dose? Content Uniformity in Over 100 Different Formulations Tested.
    Dijkers E; Polonini H; Ferreira AO
    Int J Pharm Compd; 2020; 24(5):408-412. PubMed ID: 32886639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of compounding and storage conditions on stability of pergolide mesylate.
    Davis JL; Kirk LM; Davidson GS; Papich MG
    J Am Vet Med Assoc; 2009 Feb; 234(3):385-9. PubMed ID: 19210262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development.
    Orubu ES; Okwelogu C; Opanuga O; Nunn T; Tuleu C
    Health Policy Plan; 2017 Mar; 32(2):225-235. PubMed ID: 28207051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a standardized intranet database of formulation records for nonsterile compounding, part 1.
    Evans A; Haile M; Anderson K
    Int J Pharm Compd; 2010; 14(5):401-5. PubMed ID: 23965584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
    Lam MS
    Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Errors detected in pediatric oral liquid medication doses prepared in an automated workflow management system.
    Bledsoe S; Van Buskirk A; Falconer RJ; Hollon A; Hoebing W; Jokic S
    Am J Health Syst Pharm; 2018 Feb; 75(3):127-131. PubMed ID: 29371193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of testosterone concentrations in compounded testosterone products.
    Grober ED; Garbens A; Božović A; Kulasingam V; Fanipour M; Diamandis EP
    J Sex Med; 2015 Jun; 12(6):1381-8. PubMed ID: 25963000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compounding parenteral nutrition: reducing the risks.
    Curtis C; Sacks GS
    Nutr Clin Pract; 2009; 24(4):441-6. PubMed ID: 19605798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a systematic risk analysis method to improve safety in the production of paediatric parenteral nutrition solutions.
    Bonnabry P; Cingria L; Sadeghipour F; Ing H; Fonzo-Christe C; Pfister RE
    Qual Saf Health Care; 2005 Apr; 14(2):93-8. PubMed ID: 15805453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes.
    Isles M
    Int J Risk Saf Med; 2020; 31(3):133-144. PubMed ID: 32538874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical Compounding in Portuguese Community Pharmacies: CHARACTERIZATION AND FUTURE PERSPECTIVES.
    Palmeira-de-Oliveira R; Macedo M; Machado RM; Pacheco AF; Palmeira-de-Oliveira A; Martinez-de-Oliveira J; Duarte P
    Int J Pharm Compd; 2016; 20(2):114-22. PubMed ID: 27323423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compounding practices in Iran.
    Goodarzi N; Niknam S; Akbarzadeh T; Gholami K
    Int J Pharm Compd; 2014; 18(2):112-6. PubMed ID: 24881113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.